Singapore, Nov. 5 -- In a move to better serve people living with and without diabetes, Boehringer Ingelheim and Eli Lilly and Company will modernise their current alliance as of 1 January 2020 and focus its combined expertise and investment on the continued development and commercialisation of Jardiance(R) (empagliflozin) in type 2 diabetes, heart failure, and chronic kidney disease. Trajenta(R) (linagliptin) and Basaglar(R) (insulin glargine) continue to be part of the Alliance, with primary responsibility for development and commercialisation led by the innovator company. Boehringer Ingelheim will continue as strategic lead for Trajenta(R), and Lilly for Basaglar(R).

Under the amended and restated agreement, there will be a revised ma...